AbbVie will acquire Apogee Therapeutics for $10.9 billion in cash, paying $135.11 per share, representing a roughly 49-50% premium over Apogee's previous closing price. The deal is expected to close in the third quarter of 2026, subject to regulatory and shareholder approvals.
The acquisition is AbbVie's largest in over five years and is designed to significantly bolster its immunology and inflammation (I&I) pipeline, its largest business segment.
Apogee's lead asset, zumilokibart (APG777), is a long-acting, half-life extended monoclonal antibody targeting IL-13, currently in late-stage development for atopic dermatitis (eczema) and being positioned as a potential challenger to Dupixent (dupilumab).
Apogee's pipeline also includes other long-acting I&I candidates, such as APG273, a combination of zumilokibart and an anti-TSLP antibody for asthma, and other combinations and antibodies for respiratory and other inflammatory diseases.
Sources:
AbbVie to Acquire Apogee Therapeutics for $10.9B
AbbVie strikes $10.9 billion deal for Apogee Therapeutics
AbbVie Strikes $10.9 Billion Deal for Apogee Therapeutics
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology ...
AbbVie to buy Apogee Therapeutics in nearly $11B deal - STAT News
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash (1)
AbbVie (ABBV) Is Buying Apogee Therapeutics For $10.9 Billion
AbbVie to acquire Apogee, staking nearly $11B on long-acting ...
AbbVie's biggest deal since 2019 could land soon
AbbVie inks $10.9B Apogee buyout to bag eczema prospect
AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion - WSJ
Watch AbbVie to Buy Apogee Therapeutics for $10.9 Billion
AbbVie strikes $10.9B Apogee buy to challenge juggernaut Dupixent
Joanna Sadowska, PhD, EMBA's Post - LinkedIn
AbbVie closes in on nearly $11bn deal for biotech Apogee ...